News | November 28, 2025
GV20 Therapeutics hits milestone in AI-driven cancer therapy collaboration with Mitsubishi Tanabe Pharma
GV20 received an upfront payment and is eligible for additional milestone payments
GV20 received an upfront payment and is eligible for additional milestone payments
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Subscribe To Our Newsletter & Stay Updated
